Novel 6a,12b-Dihydro-6H,7H-chromeno[3,4-c] chromen-6-ones: Synthesis, Structure and Antifungal Activity.

A new series of coumarin derivatives, 7-hydroxy-7-(trifluoromethyl)-6a,12b-dihydro-6H,7H-chromeno[3,4-c]chromen-6-ones 3a-p, were synthesized via Michael addition, transesterification and nucleophilic addition from the reaction of 3-trifluoroacetyl coumarins and phenols in the presence of an organic base. The products were characterized by infrared spectroscopy (IR), hydrogen nuclear magnetic resonance spectroscopy (1H-NMR), carbon nuclear magnetic resonance spectroscopy (13C-NMR) and high-resolution mass spectrometer (HRMS). Single crystal X-ray analysis of compounds 3a and 3n clearly confirmed their assigned chemical structures and their twisted conformations. Compound 3a crystallized in the orthorhombic system, Pbca, in which a = 8.6244(2) Å, b = 17.4245(4) Å, c = 22.5188(6) Å, α = 90°, β = 90°, γ = 90°, v = 3384.02(14) Å3, and z = 8. In addition, the mycelial growth rate method was used to examine the in vitro antifungal activities of the title compounds 3a-p against Fusarium graminearum and Fusarium monitiforme at 500 µg/mL. The results showed that compound 3l exhibited significant anti-Fusarium monitiforme activity with inhibitory index of 84.6%.

1. Introduction

Many natural compounds, such as coumarins, have commonly been used as meaningful lead compounds in the founding of some newer pharmaceuticals [1,2]. Coumarins belong to a class of notable heterocycle compounds containing oxygen, which exhibit various biological activities, including antioxidant [3], antitubercular [4], antitumor [5], antifungal [6], antibacterial [7], antiviral [8], antileishmanial [9], and anticancer [10] activities.

4-Arylcoumarins (neoflavones), present in many natural compounds, are considered important privileged structures due to their diverse biological activities, such as anticancer [11], antioxidant [12], antimicrobial [13], antiprotozoal [14] and antifungal activities [15]. Many studies have focused on the synthetic methods and structure-activity relationship research of 4-arylcoumarins, expecting to discover novel lead compounds [16].

Recently, heterocyclic fused coumarin derivatives from natural or non-natural products have attracted great interest from chemists and pharmaceutical scientists. For instance, pyrano-fused coumarin derivatives have shown much higher antifungal activities [17], and compounds containing thieno[3,2-c]coumarin and pyrazolo[4,3-c]coumarin frameworks demonstrated considerable antifungal and antibacterial activities in the in vitro test systems [18].

The attachment of a fluorine atom or fluorine-containing functional groups to heterocycle molecules often results in an increase in their lipophilicity, metabolic stability and bioactivity [19]. Trifluoromethyl ketones can be used as a typical structural framework to incorporate CF3 in the target compounds [20,21,22,23]. Keeping these aspects in mind, we adopted 3-trifluoroacetyl coumarins as a building block to synthesize novel coumarins containing fluorine [24].

Here, we report the unexpected synthesis of a series of novel dihydrocoumarins or benzopyran fused dihydrocoumarins, chromeno [3,4-c]chromen-6-ones and the preliminary evaluation of their antifungal activities.

2. Results and Discussion

2.1. Chemistry

Fan et al. reported a tandem reaction of α,β-unsaturated trifluoromethyl ketones with 2-naphthol to obtain the corresponding benzo[f]chromene derivatives in the presence of catalysts with a one-pot reaction (Scheme 1) [25]. According to the literature, an 1,4-addition reaction should take place between α,β-unsaturated trifluoromethyl ketones and 2-naphthols under the catalysis of a weak base.

Scheme 1

A base-catalyzed cycloaddition reaction of unsaturated ketones with phenols.

Inspired by Fan’s work, we anticipated synthesizing 3-hydroxy-3-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-2-one (A) first and then 3-(trifluoromethyl)-2H,10cH-benzo[f]chromeno[3,4-c]chromen-2-one (B) by using coumarins containing CF3 (1a) and 2-naphthol as starting materials in a preliminary experiment (Scheme 2). However, we did not obtain the expected products (A and B). Two new dihydrocoumarin derivatives, 1-(2-hydroxyphenyl)-3-oxo-2-(2,2,2-trifluoroacetyl)-2,3-dihydro-1H-benzo[f]chromen-2-ide (C) and 2-hydroxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3a), were unexpectedly synthesized instead.

Scheme 2

Synthesis of 3-(trifluoroacetyl)coumarin with 2-naphthol.

Dihydrocoumarin is an important core structure of many bioactive compounds. For example, the derivatives of dihydrocoumarin have dual physiological activities in plants and various pharmacological effects on the human body, such as antioxidant, antiviral and antibacterial effects [26,27]. Therefore, it is necessary to explore whether this reaction can be developed into a new method for the preparation of dihydrocoumarin derivatives.

We initiated the model reaction of 3-(trifluoroacetyl)coumarin (1a) with 2-naphthol (2a) to establish optimal reaction conditions. The results of the optimization were presented in Table 1.

Table 1

The screening of catalysts and acidifiers a.

Entry	Base	Acid	t (h)	Yield b (%)
1	i-Pr2NEt	HCl	2	85
2	NEt3	HCl	2	85
3	DBU	HCl	2	80
4	DMAP	HCl	2	4
5	NMI	HCl	2	3
6	Py	HCl	2	trace
7	NMM	HCl	2	62
8	TMEDA	HCl	2	29
9	DABCO	HCl	2	13
10	K2CO3	HCl	2	trace
11	K2CO3 + TEBA	HCl	2	24
12	KF	HCl	2	8
13	NEt3	Conc. H2SO4	2	85
14	NEt3	TFA	2	74
15	NEt3	p-TsOH	2	20
16	NEt3	Citric acid	2	38
17	NEt3	Conc. H2SO4	DCE	78
18	NEt3	Conc. H2SO4	THF	24
19	NEt3	Conc. H2SO4	CHCl3	7
20	NEt3	Conc. H2SO4	dioxane	3
21 c	NEt3	Conc. H2SO4	CH3CN	85
22 d	NEt3	Conc. H2SO4	CH3CN	65
23 e	NEt3	Conc. H2SO4	CH3CN	71
24 c,f	NEt3	Conc. H2SO4	CH3CN	86
25 c,g	NEt3	Conc. H2SO4	CH3CN	87
26 c,h	NEt3	Conc. H2SO4	CH3CN	87
27 c,i	NEt3	Conc. H2SO4	CH3CN	89
28 c,j	NEt3	Conc. H2SO4	CH3CN	93
29 c,k	NEt3	Conc. H2SO4	CH3CN	92

a Reaction conditions: 1a (0.50 mmol), 2a (0.50 mmol), catalyst (0.50 mmol), acidifier (0.60 mmol) and dichloromethane (5 mL), 45 °C, 2 h, sealed tube. b Isolated yields. c, d, e Run at 45 ºC, 25 °C, 65 °C f n(2a):n(1a):n(NEt3) = 1:1.1:1. g n(2a):n(1a):n(NEt3) = 1:1.2:1. h n(2a):n(1a):n(NEt3) = 1:1.3:1. i n(2a):n(1a):n(NEt3) = 1:1.2:1.3. j n(2a):n(1a):n(NEt3) = 1:1.2:1.4. k n(2a):n(1a):n(NEt3) = 1:1.2:1.5.

The reaction proceeded satisfactorily at 45 °C in dichloromethane (DCM) using N,N-diisopropylethylamine (i-Pr2NEt) or triethylamine (NEt3) as a catalyst, resulting in a yield of 85% (Table 1, Entries 1 and 2). If the base was changed to a strong base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), the yield slightly decreased (80%) (Table 1, Entry 3). None of the other bases, such as dimethylaminopyridine (DMAP), N-methyl imidazole (NMI), Py, N-methylmorpholine (NMM), tetramethylethylenediamine (TMEDA), 1,4-diazabicyclooctane triethylenediamine (DABCO) and inorganic bases, could produce good yields (Table 1, Entries 4–12). For acidifiers, the results showed that the best yield of 85% was obtained in the presence of hydrochloric acid or concentrated sulfuric acid (Table 1, Entries 2 and 13).

Further experiment indicated that this reaction was sensitive to solvents. The yield was compared to that in DCM when being carried out in CH3CN, but dropped significantly when in 1,2-dichloroethane (1,2-DCE), tetrahydrofuran (THF), CHCl3 and dioxane (Table 1, Entries 17–20). Moreover, increasing or lowering the reaction temperature resulted in a decreased yield (Table 1, Entries 21–23) and 45 °C was identified as the ideal reaction temperature for this reaction. Gratifyingly, when the mole ratio of 2a, 1a and NEt3 was changed from 1:1:1 to 1:1.2:1.4, the reaction gave the best yield (93%) of 3a (Table 1, Entries 24–29). Further increasing the ratio of 2a, 1a and NEt3 failed to provide a better result.

Sixteen coumarin derivatives, 6a,12b-dihydro-6H,7H-chromeno[3,4-c] chromen-6-ones, were prepared from 3-(trifluoroacetyl)coumarin (1) and phenols or 2-naphthol (2), in the presence of NEt3 as a catalyst and hydrochloric acid as an acidifier (Scheme 3 and Table 2).

Scheme 3

Synthesis of compounds through reaction of 1 and 2.

Table 2

Synthesis of compounds 3a–p.

Entry	R1	R2	R3	T (°C)	t/h	Product a	Yield b (%)
1	H	H	-	45	1.5	3a	93
2	8-OCH3	H	-	45	0.3	3b	90
3	7-OCH3	H	-	45	1.5	3c	94
4	6-CH3	H	-	45	1.5	3d	91
5	6-Br	H	-	45	0.5	3e	92
6	H	Br	-	45	1.5	3f	94
7	8-OCH3	Br	-	45	1	3g	89
8	7-OCH3	Br	-	45	1	3h	90
9	6-Cl	Br	-	45	1	3i	91
10	H	CN	-	45	2	3j	88
11	7-OCH3	CN	-	45	2	3k	89
12 c	H	-	H	65	5	3l	65
13 c	H	-	3-OH	65	3	3m	74
14 c	8-OCH3	-	4-OH	65	6	3n	80
15 c	6-Cl	-	4-OH	65	4	3o	82
16 c	H	-	3-OH, 5-CH3	65	6	3p	87

a Reaction conditions: 1a (0.64 mmol), 2a (0.50 mmol) and NEt3 (0.71 mmol) carried out in a pressure vial at 45 °C by high-performance liquid chromatography (HPLC) tracking. b Yield of isolated product. c Run at 65 °C.

As seen from Table 2, a variety of coumarins bearing either electron-withdrawing or electron-donating groups on the aryl ring could be transformed into the corresponding novel dihydrocoumarin compounds with CF3, 3a–p, with good to excellent yields (65–94%) by this simple procedure (Scheme 3). The reactions between coumarins 1 and 2-naphthols proceeded smoothly in most cases to give the products 3a–k at a relatively lower temperature (45 °C) in a short time (0.3–2 h) (Entries 1–11). However, the reactions of coumarins 1 with phenols required a higher temperature (65 °C) and longer time (3–6 h) for a lower yield, below 90% (Entries 13–16). From this point of view, the electronic density of 2-naphthols was crucial for this reaction, and the electron-donating group on the naphthalene ring was favorable to the reaction rate and yield. Indeed, the yields decreased slightly in the case of strong electron-withdrawing groups, such as CN, on the naphthalene ring, and a slightly longer reaction time of 2 h was needed (Entries 10 and 11). The results were similar for the reactions between coumarins 1 and phenols. It was not until there were strong electron-donating groups, such as OH, on the phenol ring that the reactions could run smoothly at a higher temperature (65 °C) and longer times of 3–6 h (Entries 12–16).

2.2. Structural Characterization of Chromenes

The structures of the synthesized compounds were confirmed by 1H-NMR, 13C-NMR, IR, and HRMS. For example, the 1H-NMR spectrum of 3a showed two doublet signals for CH at 3.72 ppm and 5.26 ppm, respectively, a broad singlet signal for OH at 7.48 ppm and a multiplet signal at 6.59–8.06 ppm for aromatic protons. The downfield shift in the signal of two protons at the 3- and 4-positions, which appeared at 3.0 ppm and 4.2 ppm, respectively, in reported 3,4-dihydrocoumarins [13], was caused by the inductive effects of neighboring OH and CF3 groups. The decoupled 13C-NMR spectrum of 3a showed 17 distinct resonance structures, in agreement with the proposed structure. Among them, the two quartet signals for C-CF3 at 95.71 ppm and CF3 at 122.13 ppm for which 2JC,F = 33 Hz and 1JC,F = 286 Hz, respectively, were observed. The IR spectrum of 3a displayed characteristic OH, C=O and C-F vibrations at 3419, 1728 and 822 cm–1, respectively. The HRMS data for 3a showed the molecular ion peak at m/z [M − H]+ was 385.0688, consistent with the calculated value of 385.0688.

By cooling the solutions of 3a and 3n in ethyl acetate, single crystals suitable for X-ray crystallographic analysis were obtained, and their crystal structures are shown in Figure 1. Compound 3a has a twisted conformation. Its benzene ring and naphthalene ring are connected by the sp3 carbon atom of C11 with a C10–C11–C14 angle of 115.01(16)°, and a dihedral angle of 72.776° between the benzene ring and the naphthalene ring is observed. Interestingly, the rotation of the chiral carbon atoms of C11 and C12 are restricted by intramolecular hydrogen bonding between H on C12 and C11 and F in trifluoromethyl groups, with CH···F distances of 2.519 and 2.344 Å, respectively. Moreover, the adjacent molecules are connected by intermolecular hydrogen bonding with a distance of 2.610 Å, which is almost equal to the van der Waals radius (2.6 Å) [28]. In comparison to 3a, 3n also has a twisted conformation. However, two benzene rings are almost perpendicular to each other with a dihedral angle of 89.045°, and the C4–C3–C10 angle of 113.38(16)° is slightly narrowed in comparison to that in 3a. In addition, 3n shows weak intermolecular interactions with a centroid distance of 4.126 Å between adjacent methoxy-substituted benzene rings (Figure 1d). Both compounds 3a and 3n exhibit three chiral carbon atoms, C11, C12, and C21 and C2, C3, and C16, respectively. The refinement information of compounds 3a (C21H13F3O4) and 3n (C18H13F3O6) is summarized in the Supplementary Materials.

Figure 1

Thermal ellipsoid (30%) drawings of compound 3a (a); packing of the crystal structure of 3a (b); thermal ellipsoid (30%) drawings of compound 3n (c); and intermolecular hydrogen bonding of compound 3n (d). Note: yellow, carbon; white, hydrogen; red, oxygen; green, fluorine.

2.3. Reaction Mechanism

To speculate on the mechanism of the reaction, we obtained the crystals of compound 3a before acidification, and it was ammonium salt 3a of compound 3a, being formed from the reaction between Et3N and DCM (Figure 2). Compound 3a exists in an open form with a free carbonyl group attached to -CF3 in the presence of base and easily forms a semiacetal structure with a stable six-membered ring by internal nucleophilic attack of the OH group to an active C=O group after acidification.

Figure 2

The ammonium salt 3a of compound 3a (CCDC 1900315). Note: yellow, carbon; white, hydrogen; red, oxygen; green, fluorine; blue, nitrogen; purple, chlorine.

Scheme 4 shows plausible pathways for the reaction. First, the 1,4-nucleophilic addition of 2-naphthol (2) to 3-trifluoroacetyl coumarin 1 with an α,β-unsaturated ketone structure generates the carbon anion intermediate I. It then forms enolate anion II by H-transformation. Intermediate II is next transformed into a new coumarin with phenoxy anion III through nucleophilic attack by a naphthalenyl oxyanion at the initial ester group of coumarin with slightly stronger basicity as the driving force. The subsequent addition of a phenoxy anion to the electrophilic carbon of -COCF3 group happened to furnish annulation product IV, forming the final title compound 3a with a semiacetal structure after acidification.

Scheme 4

Plausible mechanism for compound 3a.

2.4. In Vitro Antifungal Assay

The antifungal activities of the target compounds 3a–p were evaluated against Fusarium graminearum and Fusarium monitiforme by the mycelial growth rate method [29] at 500 µg/mL, using triazolone (100 µg/mL) as the positive control. The results of the antifungal activities were shown in Figure 3.

Figure 3

Antifungal activity of the target compounds 3a–p, against—Fusarium graminearum (a) and Fusarium monitiforme (b).

The bioassay results for Fusarium graminearum indicated that, except for compound 3h, all the target compounds showed antifungal activities to some extent, with an inhibitory index in the range of 13.4–62.4%. The inhibitory index of compounds 3a and 3l were 42.9% and 55%, respectively. From the activity results for the derivatives (3b–k) of compound 3a obtained by structure modification, compared with compound 3a, compounds 3b, 3e and 3f showed greater inhibition of F. graminearum, with inhibitory indexes of 52.2%, 58.4% and 62.4%, respectively.

The obtained findings suggested that a functional group, such as bromine, introduced into compound 3a could substantially contribute to the antifungal efficacy of its derivatives. However, the derivatives (3m–p) of compound 3l, whether bearing electron-donating or electron-withdrawing groups, all showed lower antifungal activities against F. graminearum than that of compound 3l.

Moreover, the inhibitory index of compound 3l against F. monitiforme (84.6%) was much higher than that of compound 3a (17.9%), which indicated that compared with the benzene ring, the naphthalene ring at the 4-position of dihydrocoumarin is unfavorable for activity against F. monitiforme. However, the compounds 3b–k modified from compound 3a, except compound 3h, all had higher antifungal activities against F. monitiforme (inhibitory index: 21.2–59.6%) than compound 3a. The reason may be that the introduction of a functional group can increase the antifungal activity. Similar to the antifungal results against F. graminearum, the compounds (3m–p) modified from compound 3l all showed lower antifungal activities against F. monitiforme (inhibitory index: 16.8%–57.4%) than compound 3l. Further research about structure and activity is in progress.

3. Materials and Methods

3.1. General Information

HPLC analyses were performed with Thermo Fisher U-3000 (Chromatographic column: XDB-C18 column with MeOH-H2O as the eluent, (Thermo Fisher scientific Co., Waltham, MA, USA) equipped with an UltiMate 3000UV detector (Thermo Fisher scientific Co., Waltham, MA, USA). Melting points were determined on an X-5 digital microscopic melting-point apparatus (Beijing Tech Instruments Co., Beijing, China) and were uncorrected. High resolution mass spectra were obtained using a Waters Q-Tof MicroTM instrument (Waters Co., MA, USA). NMR spectra were recorded on a Bruker DPX-400 spectrometer (Bruker Optics Co., Ettlingen, baden-wuerttemberg, Germany) in dimethyl sulfoxide- d6 (DMSO-d6) or chloroform-D (CDCl3) using tetramethylsilane as the internal standard. Chemical shifts (δ) were reported in ppm, and J values were reported in Hertz. The IR spectra were recorded on a Thermo IS10 FT-IR spectrometer (Thermo scientific Co., Shenzhen, Guangdong, China), and the frequencies were reported in cm−1. X-ray images were obtained with a Rigaku RAXIAS-IV type diffractometer (Rigaku Corporation Co., Tokyo, Japan).

The starting materials (1) were obtained according to the reported procedure [30]. All other reagents were acquired from commercial sources and utilized without further purification.

3.2. General Synthetic Procedures for Compounds

Typical procedure for the synthesis of compound 3a: compound 1 (0.64 mmol), naphthol (0.50 mmol), NEt3 (0.71 mmol) and 5 mL CH3CN were added to a pressure vial. The reaction mixture was stirred at 45 °C for 1.5 h (HPLC tracking reaction), and then cooled down to room temperature. After the addition of concentrated H2SO4 (0.71 mmol), the resulting mixture was stirred at room temperature for 2 h. The crude reaction mixture was concentrated by rotary evaporator, and dissoloved in DCM 30 mL. Then it was washed with water (15 mL × 3) and the organic layers were dried with Na2SO4, filtered, and concentrated in vacuo. A white crystal was obtained after crystallization from ethyl acetate-petroleum ether (0.183 g, 93%).

3.3. Biological Assays

The antifungal activity of synthesized compounds 3a–p was tested against two pathogenic fungi, namely, Fusarium graminearum and Fusarium monitiforme, by the poison plate technique at a concentration of 500 µg/mL. The two species of fungi were incubated in potato dextrose agar medium at 25 ± 1 °C for five days to obtain new mycelia for the antifungal assay, and then mycelia as disks of approximately 0.70 cm diameter cut from the culture medium were picked up with a sterilized inoculation needle and inoculated into the center of a PDA plate. The test compounds were dissolved in dimethyl sulfoxide (1 mL) then diluted to a 7500 µg/mL drug solution with 4% tween-80 emulsifier (1 mL) and added to the PDA medium (30 mL). The final concentration of compounds in the medium was adjusted to 500 µg/mL. The inoculated plates were incubated at 25 ± 1 °C for 3 days. Dimethyl sulfoxide was diluted with sterilized distilled water (4% tween-80) and used as the control, while the commercial fungicide triazolone (100 µg/mL) was used as the standard control. Three replicates of the experiments were performed. The radial growth of the fungal colonies was measured on the fourth day.

2-Hydroxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3a): Crystallization from ethyl acetate-petroleum ether, white crystal; M.p. 172.6~173.7 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.72 (d, J = 4 Hz, 1H, CH), 5.26 (d, J = 4 Hz, 1H, CH), 6.59 (d, J = 4 Hz, 1H, Ar-H), 6.70 (td, J1 = 8 Hz, J2 = 1.2 Hz, Ar-H), 7.12 (q, J = 4 Hz, 1H, Ar-H), 7.23~7.33 (m, 2H, Ar-H), 7.48 (s, 1H, -OH), 7.64 (td, J1 = 8 Hz, J2 = 0.8 Hz, 1H, Ar-H), 7.74 (td, J1 = 8 Hz, J2 = 1.2 Hz, 2H, Ar-H), 7.98~8.06 (m, 3H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 31.12 (q, J = 3 Hz, C1), 39.46 (C1), 95.71 (q, J = 33 Hz, C20), 116.24 (C16), 116.94 (C18), 117.60 (C8), 118.29 (C10), 122.13 (q, J = 286 Hz, C21), 122.64 (C4), 122.90 (C2), 126.20 (C3), 127.61 (C17), 128.61 (C7), 129.13 (C1), 129.92 (C19), 130.88 (C6), 131.33 (C14), 131.82 (C5), 147.44 (C9), 152.64 (C15), 168.35 (C13); IR (KBr) νmax (cm−1): 3419 (OH), 1728 (C=O), 1585 (Ar), 822 (CF3); HRMS (ESI): m/z calcd for C21H12F3O4 [M − H]+: 385.0688; found: 385.0688.

2-Hydroxy-14-methoxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3b): Crystallization from ethyl acetate-petroleum ether, white crystal; M.p. 173.7~174.5 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.67 (d, J = 4 Hz, 1H, CH), 3.88 (s, 3H, CH3), 5.22 (d, J = 4 Hz, 1H, CH), 6.13 (d, J = 4 Hz, 1H, Ar-H), 6.68 (t, J = 8 Hz, 1H, Ar-H), 6.81 (d, J = 8 Hz, 1H, Ar-H), 7.27 (d, J = 4 Hz, 1H, Ar-H), 7.47 (s, 1H, -OH), 7.58 (td, J1 = 8 Hz, J2 =0.8 Hz, 1H, Ar-H), 7.68 (td, J1 = 8 Hz, J2 = 0.8 Hz, 1H, Ar-H), 7.92~8.00 (m, 3H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 31.16 (q, J = 2 Hz, C11), 39.38 (C12), 56.30 (-OCH3), 95.97 (q, J = 26 Hz, C20), 112.34 (C17), 116.29 (C19), 116.87 (C18), 118.92 (C8), 119.40 (C10), 122.08 (q, J = 229 Hz, C21), 122.20 (C4), 122.90 (C2), 126.10 (C3), 128.49 (C7), 129.04 (C1), 130.79 (C6),, 131.27 (C14), 131.73 (C5), 142.31 (C16), 147.41 (C15), 148.65 (C9), 168.26 (C13); IR (KBr) νmax (cm−1): 3391 (OH), 1736 (C=O), 1582, 1478 (Ar), 817 (CF3); HRMS (ESI): m/z calcd for C22H15F3O5 [M − H]+: 415.0793; found: 415.0795.

2-Hydroxy-13-methoxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3c): Crystallization from ethyl acetate-petroleum ether, white crystal; M.p. 173.6~174.3 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.64 (d, J = 4 Hz, 1H, CH), 3.72 (s, 3H, CH3), 5.14 (d, J = 4 Hz, 1H, CH), 6.31 (dd, J1 = 8 Hz, J2 = 2 Hz, 1H, Ar-H), 6.42 (dd, J1 = 4 Hz, J2 = 0.8 Hz, 1H, Ar-H), 6.62 (d, J = 4 Hz, 1H, Ar-H), 7.69 (td, J1 = 8 Hz, J2 = 0.8 Hz, 1H, Ar-H), 7.92~8.00 (m, 3H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 30.59 (q, J = 3 Hz, C11), 39.64 (C12), 55.39 (-OCH3), 95.79 (q, J = 26 Hz, C20), 102.11 (C16), 109.75 (C18), 110.00 (C8), 116.38 (C14), 116.90 (C10), 122.05 (q, J = 229 Hz, C21), 122.87 (C4), 126.11 (C2), 128.25 (C3), 128.51 (C7), 129.06 (C1), 130.64 (C19), 131.29 (C6), 131.76 (C5), 147.28 (C9), 153.55 (C15), 160.87 (C17), 168.41 (C13); IR (KBr) νmax (cm−1): 3402 (OH), 1736 (C=O), 1628, 1501 (Ar), 819 (CF3); HRMS (ESI): m/z calcd for C22H15F3O5 [M − H]+: 415.0793; found: 415.0792.

2-Hydroxy-12-methyl-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3d): Crystallization from ethyl acetate-petroleum ether, white crystal; M.p. 160.2~161.1 °C; 1H-NMR (DMSO-d6, 400 MHz) δ: 1.97 (s, 3H, CH3), 3.61 (dd, J1 = 6 Hz, J2 = 1.2 Hz, 1H, CH), 5.60 (d, J = 6 Hz, 1H, CH), 6.17 (s, 1H, Ar-H), 7.02 (q, J = 8 Hz, 2H, Ar-H, OH), 7.25 (d, J = 8 Hz, 1H, Ar-H), 7.52 (t, J = 8 Hz, 1H, Ar-H), 7.62 (t, J = 8 Hz, 1H, Ar-H), 7.92 (d, J = 8 Hz, 1H, Ar-H), 8.00 (q, J = 4 Hz, 2H, Ar-H), 8.73 (d, J = 4 Hz, 1H, Ar-H); 13C-NMR (100 MHz, DMSO-d) δ: 20.89 (-CH3), 29.71 (C11), 41.54 (C12), 94.85 (q, J = 32 Hz, C20), 112.86 (C16), 115.82 (C8), 118.63 (C10), 122.66 (q, J = 288 Hz, C21), 123.31 (C4), 123.43 (C2), 125.11 (C3), 126.95 (C17), 128.00 (C7), 128.85 (C1), 129.10 (C18), 129.83 (C19), 130.61 (C14), 132.80 (C6), 133.52 (C5), 148.59 (C9), 150.30 (C15) (C13), 164.50 (C=O); IR (KBr) νmax (cm−1): 3287 (OH), 1765 (C=O), 1628, 1600 (Ar), 812 (CF3); HRMS (ESI): m/z calcd for C22H15F3O4 [M − H]+: 399.0844; found: 399.0805.

12-Bromo-2-hydroxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3e): Crystallization from ethyl acetate-petroleum ether, white crystal; M.p. 158.7~159.9 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.65 (d, J = 4 Hz, 1H, CH), 5.18 (d, J = 4 Hz, 1H, CH), 7.64 (d, J = 4 Hz, 1H, Ar-H), 6.97 (d, J = 4 Hz, 1H, Ar-H), 7.28~7.32 (m, 2H, Ar-H), 7.42 (s, 1H, -OH), 7.61 (t, J = 4 Hz, 1H, Ar-H), 7.72 (t, J = 4 Hz, 1H, Ar-H), 7.95~7.99 (m, 3H, Ar-H); 13C NMR (100 MHz, CDCl3) δ: 30.96 (C11), 39.14 (C12), 95.84 (q, J = 26 Hz, C20), 115.03 (C16), 115.32 (C18), 116.88 (C8), 119.44 (C10), 120.78 (C4), 121.93 (q, J = 229 Hz, C21), 122.47 (C2), 126.36 (C3), 128.90 (C7), 129.26 (C1), 130.11 (C17), 131.28 (C6), 131.39 (C5), 131.49 (C14), 132.99 (C19), 147.43 (C9), 151.76 (C15), 168.00 (C13); IR (KBr) νmax (cm-1): 3408 (OH), 1740 (C=O), 1628, 1471 (Ar), 809 (CF3); HRMS (ESI): m/z calcd for C21H11BrF3O4 [M − H]+: 462.9793; found: 462.9793.

7-Bromo-2-hydroxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3f): Eluent: EA:PE:AcOH = 2:8:0.1; white crystal; M.p.185.0~186.9 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.12 (d, J = 6 Hz, 1H, CH), 5.19 (d, J = 6 Hz, 1H, CH), 6.53 (d, J = 8 Hz, 1H, Ar-H), 6.80 (t, J = 8 Hz, 1H, Ar-H), 7.11 (d, J = 8 Hz, 1H, Ar-H), 7.26 (t, J = 8 Hz, 1H, Ar-H), 7.34 (d, J = 2 Hz, 1H, Ar-H), 7.41 (s, 1H, -OH), 7.80 (d, J = 8 Hz, 1H, Ar-H), 7.88~7.92 (t, J = 8 Hz, 2H, Ar-H), 8.17 (s, 1H, Ar-H); 13C NMR (100 MHz, CDCl3) δ: 31.19 (d, J = 3 Hz, C11), 39.37 (C12), 95.65 (q, J = 33 Hz, C20), 116.57 (C16), 117.74 (C18), 117.93 (C1), 118.21 (C8), 120.26 (C10), 122.09 (q, J = 287 Hz, C21), 122.73 (C4), 124.67 (C3), 127.37 (C7), 129.93 (C17), 130.10 (C19), 130.41 (C6), 131.11 (C2), 131.94 (C14), 132.39 (C5), 147.58 (C9), 152.61 (C15), 167.96 (C13); IR (KBr) νmax (cm−1): 3360 (OH), 1723 (C=O), 1583, 1479 (Ar), 758 (CF3); HRMS (ESI): m/z calcd for C21H11BrF3O4 [M − H]+: 462.9793; found: 462.9791.

7-Bromo-2-hydroxy-14-methoxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3g): Crystallization from ethyl acetate-petroleum ether, white crystal; M.p. 204.3~204.8 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.72 (d, J = 4 Hz, 1H, CH), 5.19 (d, J = 4 Hz, 1H, CH), 6.09 (d, J = 8 Hz, 1H, Ar-H), 7.33 (d, J = 8 Hz, 1H, Ar-H), 7.45 (s, 1H, -OH), 7.79 (d, J = 8 Hz, 1H, Ar-H), 7.89 (t, J = 8 Hz, 2H, Ar-H), 8.16 (s, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 31.28 (q, J = 3 Hz, C11), 39.33 (C12), 56.35 (-OCH3), 95.95 (q, J = 33 Hz, C20), 112.51 (C17), 116.67 (C19), 118.18 (C18), 118.69 (C1), 119.07 (C8), 120.20 (C10), 122.07 (q, J = 286 Hz, C21), 122.34 (C4), 124.72 (C3), 129.88 (C7), 130.37 (C6), 131.05 (C2), 131.87 (C14), 132.37 (C5), 142.33 (C16), 147.62 (C15), 148.77 (C9), 167.90 (C13); IR (KBr) νmax (cm−1): 3416 (OH), 1762 (C=O), 1580 (Ar), 865 (CF3); HRMS (ESI): m/z calcd for C22H14BrF3O5 [M − H]+: 492.9898; found: 492.9850.

7-Bromo-2-hydroxy-13-methoxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3h): Eluent: EA:PE:AcOH = 1:8:0.25; white acicular crystal; M.p. 162.1~163.0 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.65 (d, J = 8 Hz, 1H, CH), 3.74 (s, 3H, CH3), 5.08 (d, J = 8 Hz, 1H, CH), 6.32~6.38 (m, 2H, Ar-H), 6.63 (d, J = 4 Hz, 1H, Ar-H), 7.30 (d, J = 8 Hz, 1H, Ar-H), 7.37 (s, 1H, -OH), 7.76 (dd, J1 = 8 Hz, J2 = 2.4 Hz, 1H, Ar-H), 7.86 (t, J = 8 Hz, 1H, Ar-H), 8.13 (d, J = 1.6 Hz, 1H, Ar-H); 13C NMR (100 MHz, CDCl3) δ: 30.68 (q, J = 3 Hz, C11), 39.57 (C12), 55.45 (-OCH3), 95.42 (q, J = 33 Hz, C20), 102.23 (C16), 109.62 (C18), 109.89 (C1), 116.74 (C8), 118.19 (C14), 120.20 (C10), 122.03 (q, J = 286 Hz, C21), 124.67 (C4), 128.08 (C3), 129.79 (C7), 130.37 (C6), 131.07 (C2), 131.88 (C19), 132.37 (C5), 147.48 (C9), 153.57 (C15), 161.02 (C17), 168.08 (C13); IR (KBr) νmax (cm−1): 3419 (OH), 1737 (C=O), 1580, 1499 (Ar), 812 (CF3); HRMS (ESI): m/z calcd for C22H14BrF3O5 [M − H]+: 492.9898; found: 492.9510.

7-Bromo-12-chloro-2-hydroxy-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromen-3-one (3i): Eluent: EA:PE:AcOH = 1:8:0.25; white crystal; M.p. 175.3~176.1 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.70 (d, J = 6 Hz, 1H, CH), 5.15 (d, J = 6 Hz, 1H, CH), 6.47 (s, 1H, Ar-H), 7.06 (d, J = 8 Hz, 1H, Ar-H), 7.22 (d, J = 4 Hz, 1H, Ar-H), 7.35 (d, J = 8 Hz, 1H, Ar-H), 7.40 (s, 1H, -OH), 7.80~7.93 (m, 3H, Ar-H), 8.18 (s, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 31.09 (d, J = 2 Hz, C11), 39.11 (C12), 95.83 (q, J = 33 Hz, C20), 115.72 (C16), 118.20 (C1), 119.21 (C8), 119.69 (C10), 120.48 (C4), 121.94 (q, J = 286 Hz, C21), 124.26 (C3), 127.07 (C18), 127.86 (C7), 130.12 (C17), 130.27 (C19), 130.36 (C6), 131.30 (C2), 132.26 (C14), 132.47 (C5), 147.63 (C9), 151.22 (C15), 167.64 (C13); IR (KBr) νmax (cm−1): 3430 (OH), 1748 (C=O), 1583, 1504 (Ar), 812 (CF3); HRMS (ESI): m/z calcd for C21H11BrClF3O4 [M + H]+: 498.9560; found: 498.9331.

2-Hydroxy-3-oxo-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromene-8-carbonitrile (3j): Eluent: EA:PE:AcOH = 1:4:0.25; white crystal; M.p. 174.7~175.5 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.32 (dd, J1 = 16 Hz, J2 = 2 Hz, 1H, CH), 5.34 (d, J = 8 Hz, 1H, CH), 5.70 (s, 1H, -OH), 6.55 (dd, J1 = 8 Hz, J2 = 0.8 Hz, 1H, Ar-H), 6.70 (t, J = 8 Hz, 1H, Ar-H), 6.80 (d, J = 4 Hz, 1H, Ar-H), 7.09 (td, J1 = 8 Hz, J2 = 1.6 Hz, 1H, Ar-H), 7.48 (d, J = 8 Hz, 1H, Ar-H), 7.59 (dd, J1 = 8 Hz, J2 = 1.6 Hz, 1H, Ar-H), 7.87 (d, J = 12 Hz, 1H, Ar-H), 7.94 (d, J = 12 Hz, 1H, Ar-H), 8.24 (d, J = 0.8 Hz, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 31.41 (C11), 35.04 (C12), 95.53 (q, J = 33 Hz, C20), 108.76 (C1), 115.60 (C16), 118.15 (-CN), 118.87 (C18), 119.51 (C7), 122.42 (q, J = 286 Hz, C21), 121.47 (C8), 124.67 (C10), 125.98 (C3), 127.84 (C17), 128.04 (C19), 129.11 (C4), 130.00 (C5), 130.35 (C6), 132.86 (C14)), 134.54 (C2), 152.40 (C15, C9), 167.22 (C13); IR (KBr) νmax (cm−1): 3419 (OH), 2228 (CN), 1748 (C=O), 1628, 1585 (Ar), 753 (CF3); HRMS (ESI): m/z calcd for C22H12F3NO4 [M − H]+: 410.0640; found: 410.0600.

2-Hydroxy-13-methoxy-3-oxo-2-(trifluoromethyl)-2a,10c-dihydro-2H,3H-benzo[f]chromeno[3,4-c]chromene-8-carbonitrile (3k): Eluent: EA:PE:AcOH = 1:7:0.25; white acicular crystal; M.p. 169.7~170.4 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.68 (d, J = 6 Hz, 1H, CH), 3.74 (s, 3H, CH3), 5.13 (d, J = 6 Hz, 1H, CH), 5.30 (s, 1H, -OH), 6.34 (d, J = 4 Hz, 1H, Ar-H), 6.64 (d, J = 4 Hz, 1H, Ar-H), 7.25 (d, J = 4 Hz, 1H, Ar-H), 7.43 (d, J = 12 Hz, 1H, Ar-H), 7.85 (dd, J1 = 12 Hz, J2 = 2 Hz, 1H, Ar-H), 8.03 (d, J = 8 Hz, 1H, Ar-H), 8.11 (d, J = 4 Hz, 1H, Ar-H), 8.36 (s, 1H, Ar-H); 13C NMR (100 MHz, CDCl3) δ: 30.69 (q, J = 3 Hz, C11), 39.48 (C12), 55.47 (-OCH3), 95.63 (q, J = 30 Hz, C20), 102.34 (C16), 109.10 (C18), 109.93 (C1), 109.99 (-CN), 117.02 (C7), 118.43 (C14), 119.06 (C8), 121.96 (q, J = 286 Hz, C21), 124.39 (C10), 127.86 (C3), 129.08 (C4), 130.17 (C19), 131.36 (C5), 133.48 (C6), 134.92 (C2), 149.44 (C9), 153.56 (C15), 161.14 (C17), 167.55 (C13); IR (KBr) νmax (cm−1): 3430 (OH), 2228 (CN), 1742 (C=O), 1619, 1580 (Ar), 817 (CF3); HRMS (ESI): m/z calcd for C23H13F3NO4 [M − H]+: 440.0746; found: 440.0743.

7-Hydroxy-7-(trifluoromethyl)-6a,12b-dihydro-6H,7H-chromeno[3,4-c]chromen-6-one (3l): Eluent: EA:PE:AcOH = 2:8:0.25; white acicular crystal; M.p. 151.8~152.6 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.67 (d, J = 6 Hz, 1H, CH), 4.59 (d, J = 6 Hz, 1H, CH), 6.69 (d, J = 8 Hz, 1H, Ar-H), 6.91 (t, J = 8 Hz, 1H, Ar-H), 7.07 (d, J = 8 Hz, 1H, Ar-H), 7.16 (d, J = 8 Hz, 1H, Ar-H), 7.23~7.28 (m, 1H, Ar-H), 7.38 (t, J = 8 Hz, 1H, Ar-H), 7.46~7.52 (m, 2H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 34.98 (C3), 39.91 (C2), 95.50 (q, J = 32 Hz, C16), 117.47 (C12), 117.58 (C14), 118.41 (C6), 121.96 (C8), 122.01 (q, J = 287 Hz, C17), 122.54 (C13), 125.65 (C7), 127.45 (C15), 129.91 (C9), 129.99 (C10), 130.09 (C4), 149.42 (C5), 152.36 (C11), 168.11 (C1); IR (KBr) νmax (cm−1): 3414 (OH), 1726 (C=O), 1588, 1487 (Ar), 756 (CF3); HRMS (ESI): m/z calcd for C17H10F3O4 [M − H]+: 335.0531; found: 335.0298.

1,7-Dihydroxy-7-(trifluoromethyl)-6a,12b-dihydro-6H,7H-chromeno[3,4-c]chromen-6-one (3m): Eluent: EA:PE:AcOH = 1:5:0.1; white solid; M.p. 138.5~139.3 °C; 1H-NMR (CDCl3, 400 MHz) δ: 3.60 (d, J = 4 Hz, 1H, CH), 4.47 (d, J = 4 Hz, 1H, CH), 5.12 (s, 1H, -OH), 6.61 (d, J = 2 Hz, 1H, Ar-H), 6.75~6.80 (m, 2H, Ar-H), 6.87 (t, J = 4 Hz, 1H, Ar-H), 7.01 (d, J = 8 Hz, 1H, Ar-H), 7.20 (t, J = 4 Hz, 1H, Ar-H), 7.31 (d, J = 8 Hz, 1H, Ar-H); 13C NMR (100 MHz, CDCl3) δ: 34.33 (q, J = 2 Hz, C3), 40.11 (C2), 95.47 (q, J = 26 Hz, C16), 104.79 (C8), 112.71 (C12), 114.01 (C6), 117.52 (C4), 118.82 (C14), 121.98 (q, J = 229 Hz, C17), 122.49 (C13), 127.41 (C7), 129.84 (C15), 130.75 (C10), 150.13 (C5), 152.30 (C11), 156.88 (C9), 168.02 (C1); IR (KBr) νmax (cm−1): 3405 (OH), 1723 (C=O), 1625, 1597 (Ar), 758 (CF3); HRMS (ESI): m/z calcd for C17H10F3O5 [M − H]+: 351.0480; found: 351.0236.

2,7-Dihydroxy-9-methoxy-7-(trifluoromethyl)-6a,12b-dihydro-6H,7H-chromeno[3,4-c]chromen-6-one (3n): Eluent: DCM:PE:AcOH = 4:8:1; yellowish crystal; M.p. 187.8~188.5 °C; 1H-NMR (DMSO-d, 400 MHz) δ: 3.51 (d, J = 4 Hz, 1H, CH), 3.79 (s, 3H, CH3), 4.82 (d, J = 4 Hz, 1H, CH), 6.23 (s, 1H, -OH), 6.60 (dd, J1 = 8 Hz, J2 = 1.6 Hz, 1H, Ar-H), 6.87 (d, J = 8 Hz, 1H, Ar-H), 6.98~7.16 (m, 4H, Ar-H), 8.62 (s, 1H, Ar-H), 9.24 (s, 1H, -OH); 13C NMR (100 MHz, DMSO-d6) δ: 33.73 (C3), 42.18 (C2), 56.21 (-OCH3), 95.23 (q, J = 26 Hz, C16), 112.63 (C13), 112.98 (C7), 114.68 (C9), 116.71 (C15), 118.36 (C14), 121.27 (C6), 122.65 (C10), 122.69 (q, J = 289 Hz, C17), 124.47 (C4), 140.17 (C5), 144.60 (C12), 148.90 (C11), 154.33 (C8), 164.44 (C1); IR (KBr) νmax (cm−1): 3453 (OH), 1728 (C=O), 1605 (Ar), 730 (CF3); HRMS (ESI): m/z calcd for C18H12F3O6 [M − H]+: 381.0586; found: 381.0317.

11-Chloro-2,7-dihydroxy-7-(trifluoromethyl)-6a,12b-dihydro-6H,7H-chromeno[3,4-c]chromen-6-one (3o): Eluent: DCM:PE:AcOH = 4:8.5:0.5; white solid; M.p. 192.5~193.3 °C; 1H-NMR (DMSO-d6, 400 MHz) δ: 3.61 (d, J = 4 Hz, 1H, CH), 4.86 (d, J = 4 Hz, 1H, CH), 6.25 (s, 1H, -OH), 6.62 (d, J = 8 Hz, 1H, Ar-H), 6.90 (d, J = 8 Hz, 1H, Ar-H), 7.07 (d, J = 12 Hz, 1H, Ar-H), 7.43 (dd, J1 = 8 Hz, J2 = 2.4 Hz, 1H, Ar-H), 7.59 (s, 1H, Ar-H), 9.32 (s, 1H, -OH); 13C-NMR (100 MHz, DMSO-d6) δ: 33.46 (C3), 41.48 (C2), 95.35 (q, J = 32 Hz, C16), 112.77 (C12), 114.82 (C7), 116.88 (C9), 119.54 (C6), 122.25 (C14), 122.49 (q, J = 288 Hz, C17), 123.93 (C13), 126.56 (C15), 129.84 (C10), 130.79 (C4), 144.51 (C5), 149.64 (C11), 154.41 (C8), 164.13 (C1); IR (KBr) νmax (cm−1): 3273 (OH), 1731 (C=O), 1611, 1482 (Ar), 825 (CF3); HRMS (ESI): m/z calcd for C17H9ClF3O5 [M − H]+: 385.0091; found: 384.9819.

1,7-Dihydroxy-3-methyl-7-(trifluoromethyl)-6a,12b-dihydro-6H,7H-chromeno[3,4-c]chromen-6-one (3p): Crystallization from ethyl acetate-petroleum ether, white solid; M.p. 170.8~171.5 °C; 1H-NMR (CDCl3, 400 MHz) δ: 2.42 (s, 3H, CH3), 3.53 (d, J = 4 Hz, 1H, CH), 4.58 (d, J = 4 Hz, 1H, CH), 5.02 (s, 1H, -OH), 6.46 (s, 1H, -OH), 6.59 (dt, J1 = 8 Hz, J2 = 0.8 Hz, 1H, Ar-H), 6.67 (d, J = 2.4 Hz, 1H, Ar-H), 6.86 (td, J1 = 4 Hz, J2 = 0.8 Hz, 1H, Ar-H), 7.03 (dd, J1 = 8 Hz, J2 = 0.8 Hz, 1H, Ar-H), 7.21 (d, J = 4 Hz, 1H, Ar-H), 7.43 (d, J = 0.8 Hz, 1H, Ar-H); 13C-NMR (100 MHz, CDCl3) δ: 18.95 (-CH3), 31.20 (C3), 39.83 (C2), 95.82 (q, J = 26 Hz, C16), 102.53 (C12), 113.25 (C8), 114.46 (C6), 117.66 (C4), 118.43 (C14), 122.02 (q, J = 229 Hz, C17), 122.66 (C13), 126.75 (C15), 129.86 (C10), 138.93 (C7), 150.35 (C5), 152.57 (C11), 156.21 (C9), 168.39 (C1); IR (KBr) νmax (cm−1): 3461 (OH), 1706 (C=O), 1633, 1594 (Ar), 753 (CF3); HRMS (ESI): m/z calcd for C18H12F3O5 [M − H]+: 365.0637; found: 365.0378.

4. Conclusions

In conclusion, we have developed a novel strategy to obtain chromeno[3,4-c]chromen-6-ones 3a–p, a new kind of dihydrocoumarins, from the reactions of 3-trifluoroacetylcoumarin with phenols in one step. The chemical structures of the title compounds have been verified with the aid of several spectroscopic methods. The X-ray crystal structures of compounds 3a and 3n showed the twisted conformation in their cyclic structures. The antifungal activity of the compounds 3a–p was assessed against two fungal strains with the mycelial growth rate method. The preliminary results indicated that the phenyl ring at the dihydrocoumarins favors activity against Fusarium monitiforme. Compound 3l displayed the highest antifungal activity of 84.6% against Fusarium monitiforme. We continue our efforts to obtain new potent, broad spectrum and safe fluorine-bearing coumarins as antifungal drug-like candidates.